| abstract |
The invention provides an application of an aryl naphthalene lignan compound in preparing an anti-hepatic fibrosis drug. After in vitro, in vivo and molecular level experiments, the aryl naphthalene lignan compounds of the present invention have proved that they have strong anti-hepatic stellate cell proliferation, anti-hepatic fibrosis, and anti-matrix effects. Metalloproteinase-2 (MMP2), matrix metalloproteinase-9 (MMP9) and transforming growth factor-β1 (TGF-β1) all have low IC50 values, have good binding and inhibit their biological activities, so they can be used as Anti-fibrotic drugs. |